Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06101433
Status:
COMPLETED
Last Update Posted:
2023-10-26
First Post:
2023-10-11
Brief Title:
The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A
Sponsor:
Ahvaz Jundishapur University of Medical Sciences
Organization:
Ahvaz Jundishapur University of Medical Sciences
Study Overview
Official Title:
The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of Fibroblast Growth Factor-21 and Fetuin A
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this research the investigators tested the effect of 12-week supplementation with soy isoflavones on non alcoholic fatty liver disease NAFLD management and the level of fibroblast growth factor-21 FGF-21 and fetuin A as markers of NAFLD progression
Detailed Description:
Non-alcoholic fatty liver disease NAFLD accounts as a crucial health concern with a huge burden on health and economic systems The aim of the present study was to investigate the effect of soy isoflavone intake on hepatic outcomes and the level of fibroblast growth factor-21 FGF-21 and fetuin A in patients with NAFLD Fifty patients with NAFLD were randomized to either receive two tablets of soy isoflavone 100 mgd or placebo Dietary intakes anthropometric parameters the serum levels of liver function tests including alanine amino transferase ALT aspartate amino transferase AST and gamma glutamyl transferase GGT FGF-21 fetuin A and hepatic histological features by Fibroscan assessed at study initiation and after week 12
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None